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Abstract 43 
Purpose: This study investigated the effects of caffeine (C), taurine (T), caffeine and taurine 44 
co-ingestion (C+T) or placebo (P) on repeated Wingate cycling performance and associated 45 
physiological responses. 46 
Methods: Seven male team sports players participated in a randomised, single-blind, cross-47 
over study, where they completed three Wingate tests, each separated by 2-min, an hour after 48 
ingesting: C (5 mg/kg BM), T (50 mg/kg BM), C+T (5 mg/kg BM + 50 mg/kg BM) or P (5 49 
mg/kg BM) in a gelatine capsule. Performance was measured on an ergometer, whilst blood 50 
lactate, perceived exertion, heart rate (HR), mean arterial pressure (MAP) and rate pressure 51 
product (RPP) were measured at rest (pre-supplement), baseline (1-h post-supplement) and 52 
during and after exercise. 53 
Results: 54 
Magnitude-based inferences revealed that all of the supplements increased (small to 55 
moderate, likely to very likely) mean peak power (MPP), peak power (PP) and mean power 56 
(MP) compared to P, with greater MPP, PP and MP in T compared to C (small, possible). 57 
Intra-sprint fatigue index (%FIIntra) was greater in T compared to P and C (moderate, likely), 58 
whilst inter-sprint fatigue index (%FIInter) was lower in T compared to C (small, possible). C 59 
and C+T increased HR, MAP and RPP compared to P and T at baseline (moderate to very 60 
large, likely to most likely); however, these only remained higher in C compared to all 61 
conditions in the final sprint.   62 
Conclusions: T elicited greater improvements in performance compared to P, C or C+T, 63 
whilst reducing the typical chronotropic and pressor effects of C.   64 
 65 
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Introduction 93 
Taurine, a sulfur-containing amino acid, is one of the primary ingredients in the most popular 94 
energy drinks.1 In addition, most energy drinks contain caffeine, a methylxanthine drug 95 
commonly consumed by athletes as an ergogenic aid.2 Caffeine ingestion (3–6 mg/kg body 96 
mass) has been shown to improve performance across a variety of events,2 notably during 97 
intermittent, sprint performance.3-4 Whilst the role of caffeine as an ergogenic aid has been 98 
well-researched, the effects of taurine on performance are not thoroughly understood. There 99 
has been limited research examining the effect of isolated taurine ingestion on performance in 100 
healthy human participants, with one study reporting improvements in 3 km time-trial 101 
performance after acute supplementation.5 However, others have reported no effects of acute 102 
taurine supplementation on prolonged endurance performance6 or ‘unclear’ effects on 103 
anaerobic capacity.7 The effect of acute, isolated taurine supplementation on performance 104 
during intermittent, high-intensity exercise has not yet been investigated.  105 
 106 
Little is understood about the efficacy of caffeine and taurine co-ingestion on high-intensity 107 
intermittent performance, which is surprising given the high concentration of these 108 
ingredients in popular energy drinks and their purported effects. However, there are many 109 
similarities in the sites of action and proposed mechanisms of taurine and caffeine, which 110 
could alter their efficacy. For example, both caffeine8 and taurine9-11 are reported to regulate 111 
intracellular Ca2+ handling and the sensitivity of myofibrils to Ca2+ in skeletal muscle fibres. 112 
One mechanism of action shared by caffeine and taurine appears to be potentiation of 113 
ryanodine receptors.10 Whilst the capacity of caffeine to effect muscle force production via 114 
myofibrillar calcium handling at physiological concentrations (- 70 𝜇𝜇M) is still a topic of 115 
some debate,8 in vitro studies have shown that taurine’s effects on peak force (~29 %) and 116 
rate of force development (~28 %) is augmented in the presence of a physiological dose of 117 
caffeine.10 Both taurine and caffeine also have established, yet separate roles in the control of 118 
cardiovascular (CV) responses during rest and exercise.11-14 The specific roles of both 119 
caffeine and taurine on the CV system could be important for increasing capacity during 120 
intermittent exercise and recovery from intermittent bouts, which relies on the maintenance 121 
of cardiac output.15-16 Lastly, taurine and caffeine are known to act on the central nervous 122 
system (CNS) but have distinctly different mechanisms, with caffeine relying on antagonism 123 
of adenosine receptors17 to induce wakefulness, alertness18 and enhance information 124 
processing.19 This is in contrast to the suggested role of taurine as an extrasynaptic GABAA 125 
receptor agonist, which can increase network activity at various sites in the brain, such as the 126 
thalamus,20  which can reduce anxiety.  127 
 128 
Based on the above reasoning, it is feasible that the isolated effects of caffeine and taurine 129 
could interact in vivo, but it is not known how this might manifest during repeat-sprint 130 
performance. Therefore, the purpose of this study was to investigate the effect of caffeine 131 
(C), taurine (T), caffeine and taurine co-ingestion (C+T) or placebo (P) on repeated (× 3) 132 
Wingate cycling performance and associated physiological responses. It was hypothesized 133 
that all conditions would enhance performance compared to placebo but that the combined 134 
properties of caffeine and taurine would lead to an improved performance and reduced CV 135 
response during the intermittent protocol.  136 
 137 
Methods 138 
 139 
Participants 140 
Seven male University team sports players provided written informed to take part in the study 141 
(Age 20.8 ± 0.9 years; stature 1.76 ± 0.11 m; body mass 86.3 ± 10.2 kg). Given the typical 142 
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effect sizes (Cohen’s d = 0.3-1.0) reported using caffeine and taurine across the various 143 
dependent variables in this study, G*Power (Version 3.0.10) was used to calculate an a-priori 144 
sample size of seven, which was sufficient to identify differences between groups with a 145 
statistical power of 0.80. Given the statistical approach of the study, we also used Hopkins’ 146 
method (http://www.sportsci.org/2006/wghss.htm) to estimate sample size for magnitude-147 
based inferences, based on peak power reliability data from our laboratory. A sample size of 148 
6 participants was generated based on a smallest important change of 25 W (0.2 × between 149 
subject SD) and a typical error of 15 W. The chances of type I and II errors were deemed to 150 
be 5 %. The participants were instructed to maintain their normal, self-selected, diet 151 
throughout testing and reported this on the day of each trial. The participants did not eat 152 
within 2 hours of the trial. The participants were also provided with an extensive list of 153 
dietary sources containing caffeine and taurine, which they were instructed to avoid in the 24-154 
h prior to testing. The participants abstained from strenuous exercise in the 48-h before 155 
testing. Institutional ethical approval was given for this study, which was conducted in 156 
accordance with the 1964 Helsinki declaration. 157 
 158 
Design 159 
All participants reported to the laboratory on five separate occasions. During visit 1, the 160 
participants were familiarised with the ergometer and Wingate procedure. The all-out 161 
maximal nature of Wingate cycling tests was emphasized during this time. The bike was 162 
fitted to the participant during this visit, which remained consistent for the remainder of the 163 
study. On visits 2, 3, 4 and 5, the participants performed three 30-s Wingates, separated by 2-164 
min of active recovery. The trial was conducted using a randomised, single-blind, cross-over 165 
design. All trials were conducted at the same time of day and separated by 48-h.  166 
 167 
Procedure 168 
On arrival at the laboratory, the participants rested for 10-min prior to the measurement of 169 
resting heart rate (HR) (Polar FT1, Polar Electro Oy, Kempele, Finland), blood lactate 170 
concentration (B[La]) and blood pressure (BP) (OMRON Healthcare Europe B.V. 171 
Hoofddrop, Netherlands). Blood pressure was measured by occluding the left brachial artery 172 
of participants and reported as the mean arterial pressure (MAP) (MAP = DBP + 0.33 (SBP–173 
DBP)). Rate pressure product (RPP) was also reported (Systolic pressure x HR) as an 174 
indication of myocardial oxygen demand. A lancet was used to extract a capillary blood 175 
sample from the lobe of the ear to measure B[La], which was measured using a calibrated 176 
analyser (Biosen C Line, EKF diagnostic GmbH, Barleben, Germany). For all B[La] 177 
measurements, two samples were taken and the mean was calculated. Before each trial day, 178 
the participants’ body mass (kg) was recorded using a Portable Scale (MPMS-230, Marsden 179 
Weighing Group, Oxfordshire, UK) to allow for the correct dose of supplement and 180 
calculation of power output (W/kg) for the subsequent four trials.  181 
 182 
Supplementation 183 
All of the supplements were prepared in a powder form, which were measured using an 184 
analytical balance (Precisa 125A, Precisa Gravimetrics AG, Zurich, Switzerland) and 185 
ingested in a gelatine capsule. The capsules contained one of the following: caffeine (C) (5 186 
mg/kg BM), taurine (T) (50 mg/kg BM), caffeine + taurine (C+T) (5 mg/kg BM + 50 mg/kg 187 
BM) or a placebo (P) (maltodextrin) (5 mg/kg BM). The dosages of caffeine2 and taurine21 188 
followed the recommendations of recent studies. All supplements were sourced from the 189 
same company (My Protein, Manchester, UK). After ingestion, the participants rested in a 190 
seated position for 1-h in a quiet room and were observed by the investigators, after which 191 
baseline (post-supplement) measurements of B[La], HR and BP were taken. We hereafter 192 
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refer to post-supplement measurements as ‘baseline’. The 1-h timing was chosen as this 193 
accounted for the peak plasma availability of both taurine22 and caffeine23 after oral 194 
administration.  195 
 196 
Wingate protocol  197 
All tests were conducted indoors using an electronically braked cycle ergometer (Lode 198 
Excalibur Sport, Lode B.V. Medical Technology, Groningen, The Netherlands). The Wingate 199 
protocol was conducted at a load corresponding to 0.075 kg × BM and uncorrected power 200 
output was reported. Each participant completed a 5-min warm-up at 0.9 W/kg, cycling at 80 201 
revolutions per minute (rev/min). After 3-min of the warm-up, a 5-s sprint was performed at a 202 
load equal to the Wingate test. After the warm-up, a 3-min passive recovery stage was 203 
provided to allow for any final stretching and water. The exercise protocol consisted of three 204 
30-s Wingate tests, preceded by a 2-min active recovery. During the active recovery (0.9 205 
W/kg), the participants maintained a cadence of 65 rev/min. A countdown of “3, 2, 1 - GO” 206 
was given at the beginning of each test. The participant cycled as fast as possible for 30-s 207 
with standardised, non-specific verbal encouragement from the investigators. Recordings of 208 
B[La], were taken 1-min into each 2-min recovery. This procedure was repeated for the 209 
following two Wingate tests. The performance variables measured on the ergometer were: 210 
peak power (the highest power (PP) output attained over 1-s during the three Wingate tests); 211 
mean peak power (mean of the PP across the three Wingate tests; MPP), mean power 212 
(average power output of the three Wingate tests; MP), mean intra-sprint fatigue index 213 
(percentage difference between maximal and minimal power output during all of the three 214 
30-s Wingate tests combined; %FIIntra) and inter-sprint fatigue index (percentage change in 215 
mean power output between the three Wingate tests; %FIInter).24  216 
 217 
Heart rate was recorded from the start to the end of exercise and readings were recorded, 218 
alongside a rating of perceived exertion (RPE; 6-20) in the 5-sec after each sprint using a 6-219 
20 Borg scale. The ‘final’ HR hereafter describes the recording after the last Wingate sprint 220 
in each trial. Blood lactate concentration was measured 1-min after each sprint. The HR, 221 
B[La] and RPE were reported as a mean of all three Wingate tests (i.e. mean exercising HR, 222 
B[La] and RPE. Blood pressure (for reporting of MAP and RPP) was measured for a third 223 
and final time immediately after the final Wingate test, after which a 5-min cool-down was 224 
completed. The following three trials were carried out in an identical manner, using one of 225 
the four experimental conditions.  226 
 227 
 228 
Statistical analysis  229 
Based on best-practice recommendations for research in sports nutrition2, effect sizes (ES) 230 
and magnitude-based inferences (MBIs) were used to identify mechanistic differences in the 231 
dependent variables between the four experimental conditions (P, C, T and C+T). Effect sizes 232 
were defined as; trivial = 0.2; small = 0.21–0.6; moderate = 0.61–1.2; large = 1.21–1.99; very 233 
large > 2.0.25 Raw data were log-transformed to account for non-uniformity of effects. 234 
Threshold probabilities for a substantial effect based on the 90% confidence limits were: 235 
<0.5% most unlikely, 0.5–5% very unlikely, 5–25% unlikely, 25–75% possibly, 75–95% 236 
likely, 95–99.5% very likely, 99.5% most likely. Thresholds for the magnitude of the observed 237 
change in the dependent variables were determined as the within-participant standard 238 
deviation × 0.2 (small) 0.6 (moderate) and 1.2 (large). Effects with confidence limits across a 239 
likely small positive or negative change were classified as unclear. The uncertainty of effects 240 
was based on 90% confidence limits for all variables. A custom spreadsheet designed for 241 
cross-over trials was used to perform all of the calculations (http://www.sportsci.org/.).  242 
6 
 
 243 
Results 244 
Differences between experimental conditions for resting HR, resting MAP, resting RPP and 245 
resting B[La] were all mechanistically unclear, with ES ranging from trivial to small. The 246 
only exception at rest was the moderate, yet unclear, differences in B[La] between T and 247 
both C and C+T (Table 1). Post-supplementation, there were very large, most likely 248 
differences in HR between C and T and moderate, likely differences between C and P, P and 249 
T, and C+T and T. This translated to the findings for MAP, with baseline small, possible 250 
differences between C and T (Table 1). During exercise, there were small, possible 251 
differences for mean exercising HR between C and P and small, possible differences between 252 
C and C+T, with all other comparisons being trivial-small and unclear (Table 1). The final 253 
exercising HR was also different between C and C+T (small, likely), P and C+T, T and C+T 254 
and T and C (small, possible), with all other comparisons being trivial. This translated to 255 
small, possible differences in final MAP and final RPP between C and P, T and C+T, whilst 256 
all other comparisons were unclear (Table 1). All comparisons of exercising RPE were 257 
unclear (Table 1). 258 
 259 
 260 
 261 
*********Insert Table 1 here********** 262 
 263 
 264 
 265 
 266 
There were moderate, very likely differences in MPP between C and P, T and P and C+T and 267 
P. There were small, possible differences in MPP between T and C (Figure 1).  268 
 269 
 270 
*******Insert Figure 1 here******* 271 
 272 
 273 
 274 
There were moderate, likely differences in PP between T and P and C+T and P. PP was 275 
different (small, likely) between C and P, whilst there were small, possible differences 276 
between T and C (Figure 2).  277 
 278 
*******Insert Figure 2 here******* 279 
 280 
 281 
There were moderate, very likely differences in MP between T and P, with small likely 282 
differences in MP between C and P and C+T and P. Similar small, yet possible differences in 283 
MP were apparent between T and C (Figure 3).  284 
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 285 
*******Insert Figure 3 here******* 286 
 287 
There were small, possible differences in %FIInter between C and P and T and C. There were 288 
small, likely differences in %FIInter between C+T and P. Similar small, yet unclear differences 289 
were apparent between C+T and T (Figure 4). 290 
 291 
*******Insert Figure 4 here******* 292 
 293 
 294 
There were moderate, likely differences for %FIIntra between T and P and T and C. C+T 295 
showed small, unclear differences to P and C but moderate, possible differences to P (Figure 296 
5).   297 
 298 
*******Insert Figure 5 here******* 299 
 300 
Figure 6 shows the power profile for a representative participant during the three Wingate 301 
tests across each of the experimental conditions.   302 
 303 
 304 
*******Insert Figure 6 here******* 305 
 306 
 307 
There were no trial order effects for any performance measures found between consecutive 308 
trials, with all ES < 0.2 (trivial).  309 
 310 
Discussion 311 
In partial support of our hypothesis, we found that isolated caffeine, taurine and 312 
caffeine+taurine supplementation can improve performance during repeated Wingate tasks 313 
compared to placebo, by increasing MP, PP and MPP (Figures 1-3). Whilst it is known that 314 
caffeine may induce changes of this type,3-4 this is the first study to report improvements after 315 
isolated or co-ingested taurine supplementation. Moreover, the MP, PP and MPP achieved in 316 
the taurine condition was possibly greater (ES = small) than the caffeine condition (Figures 1-317 
3). The higher PP achieved in the taurine condition resulted in a greater intra-sprint fatigue 318 
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index compared to the caffeine and caffeine+taurine conditions. In other words, the taurine 319 
supplement permitted a higher power output at the expense of power maintenance within 320 
each Wingate sprint, whereas the caffeine-containing conditions did not increase power 321 
production to the same level but maintained power more effectively within sprints. However, 322 
this was not true for the inter-sprint fatigue index, where taurine supplementation improved 323 
the maintenance of power output across the three Wingate sprints (Figures 4 and 6). In 324 
mammalian studies, high levels of endogenous taurine have been reported in skeletal 325 
muscle,26 which is reduced after exhaustive exercise.27 Taurine depletion in vitro has been 326 
shown to reduce force output and increase the rate of fatigue during repeated stimulation of 327 
mouse skeletal muscle.11 The primary mode of action in skeletal muscle appears to be 328 
through intracellular membrane stabilisation, increased Ca2+ uptake and release and increased 329 
sensitivity of the contractile filaments to Ca2+; contributing to enhanced force production.9-11 330 
Taurine-depleted muscle fibres are suggested to fatigue faster than non-depleted muscle 331 
fibres due to altered SR-Ca2+ handling.11 Indeed, suppression of Ca2+ release or reuptake is an 332 
established cause of peripheral muscle fatigue.28 These proposed fatigue mechanisms could 333 
support the higher PP achieved in the taurine group (i.e. greater Ca2+ release) and the resultant 334 
greater fatigue (i.e. greater depletion and decreased availability, alongside a transient 335 
reduction in taurine concentration) within each Wingate sprint (%FIIntra); a mechanistic 336 
process that would be less useful for endurance-type exercise, as reported elsewhere6. Whilst 337 
the superior %FIInter in the taurine condition might seem at odds with these findings, it is 338 
entirely feasible that the 2-min recovery period between sprints was sufficient for the 339 
restoration of SR-Ca2+ before commencing the subsequent sprint. Indeed, the apparent 340 
inhibition of recovery between sprints in the caffeine+taurine condition compared to taurine 341 
alone might be related to a similar mechanism, whereby Ca2+ reuptake is interrupted by the 342 
competition for the same molecular site.      343 
 344 
Research has highlighted the ergogenic effects of caffeine in repeated high-intensity 345 
exercise.3-4 The combination of caffeine and taurine increased PP, MPP, MP (Figures 1-3) 346 
compared to placebo and guarded against the reduction in power within each Wingate test 347 
(Figure 5). In vitro studies have showed that physiological concentrations of taurine can 348 
improve force (~29 %) and rate of force development (~28 %) in the presence of caffeine.10 349 
On this basis, it has been proposed that the isolated effects of caffeine and taurine could 350 
interact to augment high-intensity physical performance. However, others have shown no 351 
change in force production, rate of fatigue or acute recovery after repeated stimulations of 352 
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isolated mouse skeletal muscle with caffeine and taurine co-ingestion compared to caffeine 353 
alone, with no effect of isolated taurine.29 Using doses of taurine that were larger than that of 354 
a typical energy drink (50 mg/kg BM vs. ~15-35 mg/kg BM),6-7 appeared to exaggerate the 355 
effects on repeated-sprint performance, such that that taurine supplementation alone elicited 356 
the greatest effects on power output. By implication, this also suggests that caffeine, for 357 
unknown reasons, inhibited the effect of taurine in this study. Further research is required to 358 
understand the mechanisms that explain this phenomenon during repeat-sprint cycling; 359 
however, this could be linked to the shared molecular target that both caffeine and taurine 360 
potentially act on to alter Ca2+ dynamics in skeletal muscle, which appears to be dependent 361 
on muscle fibre type.11,29  362 
 363 
Cardiovascular responses (MAP, HR and RPP) were highest in caffeine-containing 364 
conditions, 1-h after supplementation (baseline) (Table 1). This can be explained by the 365 
chronotropic effects that can be elicited by caffeine, contributing toward the acute, centrally-366 
mediated, increases in blood pressure observed after ingestion.17 However, during exercise 367 
and the final exercising measurements, HR, MAP and RPP were higher in the caffeine 368 
condition compared to placebo, taurine or caffeine+taurine. It is known that isolated taurine 369 
administration does not increase HR or blood pressure but does exert inotropic actions on the 370 
cardiac musculature12-14 particularly when Ca2+ concentration is reduced, as can be observed 371 
during exhaustive exercise.26 If taurine supplementation increased myocardial contractility 372 
and, in turn diastolic filling time per cardiac cycle, during intermittent cycling, the lower 373 
cardiac frequency (HR) might be anticipated. Indeed, such characteristics have been 374 
associated with increased recovery from exercise.16 This provides one possible explanation 375 
for the ergogenic effects of taurine in this study.  376 
 377 
It is likely that the baseline increases in HR, MAP and RPP reflect the acute effects of 378 
caffeine on the heart in caffeine-containing conditions but that the introduction of taurine 379 
(caffeine+taurine) blunted this effect at later exercising periods (Table 1). There are two 380 
potential reasons for this delayed response. Firstly, it is known that exercise-induced 381 
increases in reactive oxygen species (ROS) trigger a release of taurine from muscle during 382 
exercise.30 Therefore, it is possible that the interactive effects of caffeine and taurine on the 383 
cardiovascular system might be exercise-induced. Secondly, peak plasma levels of taurine 384 
occur approximately 1 to 2.5-h (mean = 1.5-h) after oral ingestion,22 whereas peak plasma 385 
caffeine concentration is typically reached between 0.25 to 1-h (mean = 0.5-h) after 386 
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ingestion.23 Since both supplements were administered simultaneously in the current study, it 387 
is possible that the actions of taurine on the cardiovascular system were delayed and, thus, 388 
did not induce physiological changes until after baseline conditions. Whilst more research is 389 
needed to elucidate the mechanisms that caused this response, our findings suggest that oral 390 
ingestion of taurine is capable of lowering BP and HR.  391 
 392 
Co-ingestion of taurine and caffeine has been shown to reduce HR, perhaps facilitated by 393 
taurine in response to caffeine-induced pressor effect.14 Our baseline data shows that 394 
caffeine+taurine increased HR but, after exercise, HR and other cardiovascular responses 395 
were lower than caffeine alone (Table 1). We are unsure why our data only agree with 396 
previous studies14 after our participants took part in physical exercise but various 397 
methodological differences prevent direct comparisons. For example, Bichler et al.14 did not 398 
conduct their study on exercising participants and administered lower oral doses of taurine 399 
and caffeine. Whilst further research is required to elucidate the cardiovascular effects of 400 
caffeine and taurine co-ingestion, our findings suggest that taurine can counteract the effect 401 
of caffeine on HR, MAP and RPP, as demonstrated by differences between caffeine and 402 
caffeine+taurine  at various time-points (Table 1), without compromising performance during 403 
repeat-sprint cycling.      404 
 405 
There were some limitations to this study. We have primarily focussed on peripheral causes 406 
of fatigue, without acknowledging the wider roles of both caffeine and taurine on the central 407 
nervous system.17,20 It would have been useful to measure the relative contributions of central 408 
and peripheral sources of fatigue in this study in order to identify the mechanisms that 409 
facilitate the notable performance improvements with taurine supplementation, as well as 410 
qualifying our discussion of mechanism, which have centred on Ca2+ handling in the muscle. 411 
Future research should investigate the underlying mechanisms further. We also did not take 412 
venous blood samples in this study to test for plasma caffeine or taurine concentration, nor 413 
did we follow a double-blind research design. The reasons for these choices related to 414 
participant recruitment and health and safety concerns whilst providing supplements. Our 415 
laboratory is currently working on methods to avoid venous blood sampling for verification 416 
of plasma caffeine and taurine in studies such as this.  417 
 418 
Practical applications 419 
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The superior PP, MPP and MP observed after taurine supplementation has logical importance 420 
during track cycling events. The ability to generate a high peak power may help in sprinting, 421 
standing starts or even translate into other power-based sports. Taurine supplementation 422 
might also ameliorate performance during short, high-intensity events, based on the ~3% 423 
difference in the inter-sprint fatigue index between taurine and caffeine conditions.  424 
 425 
Conclusion  426 
Oral ingestion of taurine elicited at small-to-moderate improvements in repeat-Wingate 427 
cycling compared to other conditions. Whilst taurine ingestion led to a greater rate of fatigue 428 
within each Wingate sprint, power output was maintained more effectively between 429 
successive sprints compared to caffeine or caffeine+taurine co-ingestion. Caffeine-containing 430 
supplements increased baseline (post supplementation) cardiovascular responses compared to 431 
taurine and placebo conditions but the interaction of taurine and caffeine resulted in a 432 
lowered HR, MAP and RPP in response to exercise compared to caffeine alone. Further 433 
research is needed to establish whether this effect is exercise-induced and to reveal the 434 
underlying mechanisms that explain the current findings.  435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
 444 
 445 
 446 
 447 
 448 
 449 
 450 
 451 
 452 
 453 
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544 
Table 1. Effect sizes and magnitude-based inferences for resting, baseline, and exercising heart rate (HR), blood lactate (B[La]), mean arterial pressure 545 
(MAP), rate pressure product (RPP) and rating of perceived exertion (RPE) between placebo (P), caffeine (C), taurine (T) and caffeine+taurine (C+T) 546 
conditions (n = 7). Mean ± SD are reported.  547 
 548 
 549 
Note:  Mechanistic inferences: A = Most likely; B = Very likely; C = likely; D = Possibly; E = Unclear. Qualitative outcome is reported between experimental conditions. Effect sizes (d): † = Trivial; ‡ = 550 
Small; ¥ = Moderate; * = Large or Very Large. > = mean is larger than; < = mean is smaller than; ~ = mean is equal. Symbols are used in all following Figures  551 
 552 
 553 
  Placebo (P) Caffeine (C) Taurine (T) 
Caffeine + 
Taurine (C+T)  Direction, effect size and mechanistic inference 
HR              
Resting HR (b/min) 75.3 ± 12.5 76.0 ± 8.2 74.7 ± 12.2 76.6 ± 11.2 P<C†E; P>T†E; P<C+T†E; C>T†E; C<C+T†E; T<C+T†E 
Baseline HR (b/min) 73.0 ± 11.3 79.1 ± 14.7 66.9 ± 13.5 74.0 ± 12.9 P<C‡C; P>T‡C; P<C+T†E; C>T*A; C>C+T‡E; T<C+T¥C 
Mean exercising HR (b/min) 159.6 ± 26.1 164.9 ± 26.4 161.5 ± 29.9 158.2 ± 25.1 P<C‡D; P<T†C; P<C+T†E; C>T†E; C>C+T‡D; T>C+T†E 
Final HR (b/min) 166.7 ± 21.3 169.8 ± 23.8 166.0 ± 23.0 163.3 ± 22.4 P<C‡E; P<T†E; P>C+T‡D;  C>T‡D; C>C+T‡C; T>C+T‡D 
MAP 
             Resting MAP (mmHg) 89.7 ± 12.5 90.9 ± 10.2 92.7 ± 6.5 92.4 ± 8.2 P<C†E; P<T‡E; P<C+T‡E; C<T†E; C<C+T†E; T>C+T†E 
Baseline MAP (mmHg) 92.2 ± 12.3 95.7 ± 8.3 90.6 ± 7.6 94.5 ± 9.8 P<C‡E; P>T†E; P<C+T‡E; C>T‡D; C>C+T†E; T<C+T‡E 
Final MAP (mmHg) 88.4 ± 9.7 94.4 ± 19.0 87.3 ± 5.1 88.5 ± 6.1 P<C‡C; P>T†E; P<C+T†E; C>T‡D; C>C+T‡D; T<C+T†E 
              RPP   
Resting RPP (mmHg/b/min) 9981 ± 1548 9525 ± 1623 9977 ± 1626 9454 ± 1513 P>C‡E; P>T†E; P>C+T‡E; C<T‡E; C>C+T†E; T>C+T‡E 
Baseline RPP (mmHg/b/min) 8870 ± 1243 10636 ± 2134 8645 ± 1327 9688 ± 2240 P<C¥B; P>T†E; P<C+T‡E; C>T¥B; C>C+T¥C; T<C+T¥E 
Final RPP (mmHg/b/min) 22311 ± 3809 23921 ± 5312 22150 ± 4531 22120 ± 4338 P<C‡D; P>T†E; P<C+T†E; C>T‡D; C>C+T‡D; T>C+T†E 
              B[La]       
Resting B[La] (mmol/L) 1.2 ± 0.3 1.5 ± 0.8 1.0 ± 0.2 1.5 ± 0.5 P<C‡E; P>T‡E; P<C+T‡E; C>T¥E; C~C+T‡E; T<C+T¥E 
Baseline B[La] (mmol/L) 1.1 ± 0.6 1.2 ± 0.2 0.8 ± 0.1 1.0 ± 0.1 P<C‡C; P>T‡E; P>C+T†E; C>T¥A; C>C+T‡D; T<C+T‡B 
Mean exercising B[La] (mmol/L) 8.9 ± 1.6 9.7 ± 1.9 8.6 ± 1.7 8.8 ± 1.8 P<C‡E; P>T‡E; P>C+T†E; C>T‡C; C>C+T‡C; T<C+T†E 
              RPE       
Mean exercising RPE (6-20) 18 ± 1 17 ± 1 17 ± 1 17 ± 1 P>C‡E; P>T‡E; P>C+T‡E; C~T†E; C~C+T†E; T~C+T†E 
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List of figure legends: 554 
 555 
Figure 1. Mean ± SD for mean peak power (MPP) across the three Wingate tests between conditions (n = 7). Only small-large differences are presented for 556 
clarity.  557 
 558 
Figure 2. Mean ± SD for peak power (PP) across the three Wingate tests between conditions (n = 7). Only small-large differences are presented for clarity. 559 
 560 
Figure 3. Mean ± SD for mean power (MP) across the three Wingate tests between conditions (n = 7). Only small-large differences are presented for clarity. 561 
 562 
Figure 4. Mean ± SD for the inter-sprint fatigue index (%FIInter) across the three Wingate tests between conditions (n = 7). Only small-large differences are 563 
presented for clarity.  564 
 565 
Figure 5. Mean ± SD for the intra-sprint fatigue index (%FIIntra) across the three Wingate tests between conditions (n = 7). Only small-large differences are 566 
presented for clarity.  567 
 568 
Figure 6. Power output of a representative participant during repeated Wingate tests (x 3) in the four experimental conditions (T = Taurine; C+T = Caffeine + 569 
Taurine; C = Caffeine; P = Placebo).  570 
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